Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Amphastar Pharmaceuticals, Inc. - Common Stock
(NQ:
AMPH
)
28.50
+0.95 (+3.45%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amphastar Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Amphastar Pharmaceuticals, Novavax, and Organon Shares Skyrocket, What You Need To Know
February 13, 2026
A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a...
Via
StockStory
Topics
Economy
3 Cash-Producing Stocks We Keep Off Our Radar
February 09, 2026
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...
Via
StockStory
3 Stocks Under $50 with Warning Signs
February 04, 2026
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and...
Via
StockStory
Topics
Artificial Intelligence
Why Amphastar Pharmaceuticals (AMPH) Stock Is Nosediving
January 15, 2026
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell 5.3% in the afternoon session after a Bank of America analyst lowered the firm's price target on the shares and reports...
Via
StockStory
2 Reasons to Avoid AMPH and 1 Stock to Buy Instead
January 14, 2026
Amphastar Pharmaceuticals has had an impressive run over the past six months as its shares have beaten the S&P 500 by 19.5%. The stock now trades at $27.76, marking a 31% gain. This was partly due to...
Via
StockStory
Topics
Stocks
Supply Chain
1 Profitable Stock Worth Your Attention and 2 Facing Headwinds
January 13, 2026
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...
Via
StockStory
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today
January 12, 2026
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 5.8% in the afternoon session after the company announced it had entered into an exclusive license agreement with Nanjing...
Via
StockStory
Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound
January 12, 2026
Via
ACCESS Newswire
3 Low-Volatility Stocks We Find Risky
January 07, 2026
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Via
StockStory
Amphastar Pharmaceuticals to Present at the J.P. Morgan 2026 Healthcare Conference
January 07, 2026
Via
ACCESS Newswire
Amphastar Director Sells 16,679 Shares for $441,800
↗
December 23, 2025
Amphastar is down big in 2025, but recently announced positive FDA-related news.
Via
The Motley Fool
Topics
Regulatory Compliance
3 Healthcare Stocks with Questionable Fundamentals
December 15, 2025
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have...
Via
StockStory
Topics
Stocks
Amphastar Announces FDA Approval for Teriparatide Injection
December 15, 2025
Via
ACCESS Newswire
2 Russell 2000 Stocks for Long-Term Investors and 1 Facing Challenges
December 11, 2025
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these...
Via
StockStory
1 Stock Under $50 Worth Your Attention and 2 We Brush Off
December 08, 2025
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and...
Via
StockStory
Amphastar Pharmaceuticals (AMPH) Stock Trades Up, Here Is Why
December 03, 2025
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 3.7% in the afternoon session after positive analyst sentiment and technical trading indicators pointed to potential...
Via
StockStory
Topics
Economy
Amphastar (AMPH) Q3 2025 Earnings Call Transcript
↗
November 27, 2025
Amphastar (AMPH) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Amphastar Pharmaceuticals to Present at the 37th Annual Piper Sandler Healthcare Conference
November 24, 2025
Via
ACCESS Newswire
The Ensign Group, Illumina, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know
November 21, 2025
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated...
Via
StockStory
Topics
Economy
Unpacking Q3 Earnings: Amneal (NASDAQ:AMRX) In The Context Of Other Generic Pharmaceuticals Stocks
November 19, 2025
Looking back on generic pharmaceuticals stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Amneal (NASDAQ:AMRX) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
3 Small-Cap Stocks with Questionable Fundamentals
November 17, 2025
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small...
Via
StockStory
5 Must-Read Analyst Questions From Amphastar Pharmaceuticals’s Q3 Earnings Call
November 13, 2025
Amphastar Pharmaceuticals' third quarter results for 2025 came in ahead of Wall Street's revenue and profit expectations, despite essentially flat sales compared to the prior year. The quarter was...
Via
StockStory
Topics
Earnings
Reflecting On Generic Pharmaceuticals Stocks’ Q3 Earnings: Viatris (NASDAQ:VTRS)
November 12, 2025
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Viatris (NASDAQ:VTRS) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today
November 12, 2025
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 3.9% in the afternoon session after the stock's positive momentum continued as the company reported impressive financial...
Via
StockStory
Topics
Artificial Intelligence
Supply Chain
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
November 12, 2025
Via
ACCESS Newswire
Generic Pharmaceuticals Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) Simply the Best
November 11, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Why Are Amphastar Pharmaceuticals (AMPH) Shares Soaring Today
November 10, 2025
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 10.9% in the afternoon session after the stock's positive momentum continued as the company reported third-quarter...
Via
StockStory
Topics
Artificial Intelligence
Supply Chain
AMPH Q3 Deep Dive: Pipeline Expansion and Core Product Growth Offset Margin Pressures
November 10, 2025
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported Q3 CY2025 results topping the market’s revenue expectations, but sales were flat year on year at $191.8 million. Its non-GAAP...
Via
StockStory
Why Amphastar Pharmaceuticals (AMPH) Stock Is Up Today
November 07, 2025
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 4.9% in the afternoon session after the company reported third-quarter 2025 financial results that surpassed analyst...
Via
StockStory
Topics
Artificial Intelligence
Economy
Government
The Analyst Verdict: Amphastar Pharma In The Eyes Of 4 Experts
↗
November 07, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.